Canexis Pharma – Cannabis APIs: portfolio flyer (PDF)

Canexis Pharma AG exhibits at CPHI Milan from 6 to 8 October 2026 at stand 2D98 in the Natural Extracts zone. Meetings can be booked in advance via the CPHI Event Planner. On the agenda: specifications and samples of Cannabidiol Ph. Eur., Dronabinol, cannabis extracts and distillates, GMP documentation and supply planning for 2027.

Full product catalogue with specifications, pack sizes and regulatory status available on request. Professional use only.

Canexis Pharma AG offers eight validated cannabis-based products from one Swiss EU-GMP source: Cannabidiol Ph. Eur., Dronabinol, THC- and CBD-dominant extracts and distillates, and standardized extracts with custom THC/CBD ratios. The new product flyer summarises the portfolio; the full catalogue is available on request.

Company news, production insights and CPHI Milan updates from our EU-GMP site in Schlattingen, Switzerland.

Swiss cannabis API manufacturer Canexis Pharma AG exhibits at CPHI Milan, 6–8 October 2026, at stand 2D98 in the Natural Extracts zone – presenting Cannabidiol Ph. Eur., Dronabinol (USP/DAC), THCA and GMP cannabis extracts and distillates, all manufactured in Switzerland under EU-GMP Part I and Part II licences.

Our virtual booth on PharmaCompass with the cannabinoid API portfolio overview and contact options.